Esperion Therapeutics, Inc. - 8-K Filing
Esperion Therapeutics completed its $1.1 billion acquisition by Essence Parent Inc., triggering delisting from Nasdaq and creation of contingent value rights. (Items: 1.01 Entry into a Material Definitive Agreement, 2.01 Completion of Acquisition or Disposition of Assets, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, 3.01 Notice of Delisting or Failure to Satisfy a Continuing Listing Rule or Standard; Transfer of Listing)
Tickers: $ESPR